This Biotech Stock is Developing Breakthrough Cancer Detection Tools

NanoString Technologies (NSTG) is a biotechnology company at the forefront of developing cancer diagnostic tools. 

In fact, the company uses genomic data to detect cancer early at a molecular level, as well as better target residual areas of the disease. This means NSTG effectively uses DNA to find and treat cancer before it becomes a major issue. 

And while it’s a relatively new publicly-traded company, NSTG is making progress in achieving profitability.

In its most recent quarter, NSTG reported an earnings loss per share of $0.60, largely in-line with Wall Street’s expected loss per share of $0.59. The company’s EBITDA was a loss of $17.3 million versus the expected decline of $21.5 million. 

Meanwhile, revenue came in ahead of the $32.3 million estimate at $33.9 million. 

Currently, NSTG is partnered with Parker Institute on a molecular characterization project for cellular therapies.

Through the collaboration, the companies will develop standardized approaches to cell therapy regimens that could help improve patient outcomes across a variety of cancer types. 

And as the biotech company continues to research breakthrough therapies, it could be at the forefront of a new era of cancer treatments.

World’s First $20 Trillion Drug?

Sponsored

The Alzheimer’s Association estimates that, “caring for individuals with Alzheimer’s will cost American society $20 trillion.”

Jim Cramer says a drug that could treat the disease “would be the biggest drug ever.”

The Wall Street Journal says the “financial benefits would be massive.”

One small biotech holds the key to a revolution in treating this dreaded disease.

Jeff Bezos, Goldman Sachs & a Big Pharma giant have invested billions into this unknown biotech.

And our research shows that anyone who gets in today could turn every $1,000 into $1.1 million.

Click here to learn more >>>

$2 EV Stock No One's Talking About

This company is a sneaky EV play that no one’s talking about. They’re producing an odd variation on the traditional EV that has consumers raving.

Enter your email address to receive this company’s name and ticker symbol for free.



By submitting your email address, you give Stock Market Junkie permission to deliver the report or research you’re requesting to your email inbox. As a bonus, you will also get a free subscription to one of our carefully selected marketing partners. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works

$30 Stock Freaking Out Billionaires

This stock is an industry leader in a robotics technology that is freaking out billionaires (trading for just $30).

Enter your email address to receive this company’s name and ticker symbol for free.



By submitting your email address, you give Stock Market Junkie permission to deliver the report or research you’re requesting to your email inbox. As a bonus, you will also get a free subscription to one of our carefully selected marketing partners. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works

The Best TaaS Stock Right Now

This company is set to corner the market in a self-driving technology that  could fundamentally change our entire society – much like the internet did.

Enter your email address to receive this company’s name and ticker symbol for free.



By submitting your email address, you give Stock Market Junkie permission to deliver the report or research you’re requesting to your email inbox. As a bonus, you will also get a free subscription to one of our carefully selected marketing partners. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works

Up to 20,000 IPOs All in One Day

A radical $2.1 quadrillion shift is coming to the financial markets.

Some are calling it G.T.E. and Mark Cuban, Elon Musk, Richard Branson, and even banks like J.P. Morgan are invested in the tech behind it.

Just $25 could get you in alongside these billionaires. 

Enter your email address to receive the video that reveals it all.



By submitting your email address, you give Stock Market Junkie permission to deliver the report or research you’re requesting to your email inbox. As a bonus, you will also get a free subscription to one of our carefully selected marketing partners. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works

53-cent Biotech Stock with $2 Price Target

Steve Cohen, the billionaire stock picker known for running one of the most successful hedge funds ever, has poured millions into the first stock, and it’s trading for only 53 cents.

Enter your email address to receive this company’s name and ticker symbol for free.



By submitting your email address, you give Stock Market Junkie permission to deliver the report or research you’re requesting to your email inbox. As a bonus, you will also get a free subscription to one of our carefully selected marketing partners. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works